S1PR1 and cardiac hypertrophy: We demonstrated that 4-week treatment with the G-protein-biased S1P1 agonist, SAR247799, blunted the progression of diastolic dysfunction, and reduced cardiac hypertrophy, right atrial enlargement and perivascular cardiac fibrosis.